Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Stephen Basil Thomas currently holds 40,000 shares of Eliem Therapeutics, Inc. (ELYM), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Stephen Basil Thomas has been a net neutral trader of ELYM stock. They have purchased $0 and sold $0 worth of shares.
Stephen Basil Thomas's most recent insider trade was on Jun 5, 2026, when they sold 40,000 shares at $0.00 per share.
Stephen Basil Thomas serves as Executive at Eliem Therapeutics, Inc. (ELYM). They have executed 5 insider transactions totaling $0 over their tenure at the company.
Stephen Basil Thomas holds the position of Executive at Eliem Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 2 years and currently hold a stake valued at $0.
Stephen Basil Thomas has shown a balanced trading pattern, with $0 in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a balanced approach to trading.
The largest transaction by Stephen Basil Thomas was on Jun 5, 2026, when they purchased $0 worth of CLYM shares. This transaction involved 40,000 shares at N/A per share.
Stephen Basil Thomas currently owns 40,000 shares of Eliem Therapeutics, Inc. (ELYM), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Stephen Basil Thomas's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Stephen Basil Thomas has 5 Form 4 filings on record as an insider at Eliem Therapeutics, Inc..
Set alerts for Stephen Basil Thomas and 40,000+ other insiders.